Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMNN Imunon	$0.55 -8.5%	$1.04	$0.37 ▼ $3.65	$10.58M	1.93	3.95 million shs	3.05 million shs
ONVO Organovo		$3.94	$1.56 ▼ $21.96	$3.47M	1.13	617,505 shs	243,634 shs
RLYB Rallybio	$0.43 -5.4%	$0.35	$0.22 ▼ $1.54	$18.92M	-1.17	758,138 shs	763,572 shs
SYBX Synlogic	$1.74 +3.0%	$1.22	$0.90 ▼ $1.96	$19.77M	0.55	21,419 shs	286,460 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMNN Imunon	+22.30%	-7.18%	-46.61%	-32.21%	-58.39%
ONVO Organovo	0.00%	0.00%	0.00%	+18.60%	-71.06%
RLYB Rallybio	+5.21%	+14.82%	+34.53%	+81.88%	-67.29%
SYBX Synlogic	+11.92%	+38.41%	+37.40%	+59.43%	+2.46%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMNN Imunon	2.1268 of 5 stars	3.4	4.0	0.0	0.0	1.6	0.0	0.6
ONVO Organovo	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RLYB Rallybio	2.6965 of 5 stars	3.0	3.0	0.0	0.0	2.6	1.7	1.3
SYBX Synlogic	0.9838 of 5 stars	0.0	3.0	0.0	0.0	2.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMNN Imunon	2.75	Moderate Buy	$15.50	2,707.97% Upside
ONVO Organovo	0.00	N/A	N/A	N/A
RLYB Rallybio	2.00	Hold	$10.00	2,225.58% Upside
SYBX Synlogic	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ONVO, IMNN, RLYB, and SYBX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	IMNN Imunon	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/19/2025	IMNN Imunon	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/13/2025	IMNN Imunon	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$29.00 ➝ $17.00
5/7/2025	IMNN Imunon	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$29.00 ➝ $29.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMNN Imunon	$500K	19.36	N/A	N/A	$0.29 per share	1.90
ONVO Organovo	$122K	0.00	N/A	N/A	$0.02 per share	0.00
RLYB Rallybio	$640K	27.96	N/A	N/A	$1.49 per share	0.29
SYBX Synlogic	$10K	2,035.80	N/A	N/A	$1.09 per share	1.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMNN Imunon	-$18.62M	-$1.36	N/A	N/A	N/A	N/A	-427.98%	-175.03%	8/13/2025 (Estimated)
ONVO Organovo	-$14.67M	-$10.20	N/A	N/A	N/A	-10,151.64%	-346.26%	-187.53%	N/A
RLYB Rallybio	-$57.78M	-$1.09	N/A	N/A	N/A	-5,682.19%	-72.31%	-64.78%	8/14/2025 (Estimated)
SYBX Synlogic	-$23.36M	-$2.51	N/A	N/A	N/A	N/A	10.91%	7.47%	8/6/2025 (Estimated)

Latest ONVO, IMNN, RLYB, and SYBX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	SYBX Synlogic	-$0.13	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	IMNN Imunon	-$0.24	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	IMNN Imunon	-$0.35	-$0.28	+$0.07	-$0.28	N/A	N/A
5/8/2025	Q1 2025	RLYB Rallybio	-$0.21	-$0.21	N/A	-$0.21	N/A	$0.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMNN Imunon	N/A	N/A	N/A	N/A	N/A
ONVO Organovo	N/A	N/A	N/A	N/A	N/A
RLYB Rallybio	N/A	N/A	N/A	N/A	N/A
SYBX Synlogic	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMNN Imunon	N/A	0.88	0.88
ONVO Organovo	N/A	0.72	1.72
RLYB Rallybio	N/A	14.68	14.68
SYBX Synlogic	N/A	3.68	3.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMNN Imunon	4.47%
ONVO Organovo	8.23%
RLYB Rallybio	90.34%
SYBX Synlogic	63.40%

Insider Ownership

Company	Insider Ownership
IMNN Imunon	5.96%
ONVO Organovo	3.72%
RLYB Rallybio	8.70%
SYBX Synlogic	3.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMNN Imunon	30	17.54 million	16.50 million	Not Optionable
ONVO Organovo	20	1.70 million	14.79 million	Optionable
RLYB Rallybio	40	41.61 million	37.99 million	Not Optionable
SYBX Synlogic	80	11.70 million	11.34 million	Optionable

ONVO, IMNN, RLYB, and SYBX Headlines

Recent News About These Companies

Synlogic, Inc. (SYBX) Latest Stock News & Headlines - Yahoo Finance

June 28, 2025 | finance.yahoo.com

Synlogic's executive sells shares worth $2,802

February 5, 2025 | msn.com

Synlogic Reports Q3 2024 Financial Outcomes

November 14, 2024 | markets.businessinsider.com

Synlogic, Inc.: Synlogic Reports Third Quarter 2024 Financial Results

November 13, 2024 | finanznachrichten.de

Synlogic Reports Third Quarter 2024 Financial Results

November 12, 2024 | globenewswire.com

Synlogic preps phenylketonuria drug for phase 3 after mid-stage win

November 6, 2024 | pharmaphorum.comP

Synlogic, Inc. (0A8U.L)

August 24, 2024 | nz.finance.yahoo.com

MIN.SG,0P0001I7V6,0 (MIN.SG)

August 16, 2024 | nz.finance.yahoo.com

Maintaining Hold on Synlogic Amid Strategic Reassessment and Financial Uncertainty

August 14, 2024 | markets.businessinsider.com

Synlogic, Inc.: Synlogic Reports Second Quarter 2024 Financial Results

August 8, 2024 | finanznachrichten.de

SYBX Stock Earnings: Synlogic Beats EPS for Q2 2024

August 8, 2024 | investorplace.com

Synlogic Reports Second Quarter 2024 Financial Results

August 8, 2024 | globenewswire.com

Synlogic Inc.

July 21, 2024 | wsj.com

Synlogic Inc SYBX

July 21, 2024 | morningstar.comM

The Summer Stock Exodus: 3 Companies to Ditch Before the Heat Hits

May 23, 2024 | investorplace.com

Hold Rating Maintained for Synlogic Amidst Setbacks and Financial Uncertainties

May 16, 2024 | markets.businessinsider.com

SYBX Stock Earnings: Synlogic Misses EPS, Misses Revenue for Q1 2024

May 14, 2024 | investorplace.com

Synlogic, Inc.: Synlogic Reports First Quarter 2024 Financial Results

May 14, 2024 | finanznachrichten.de

Synlogic Flat on Q1 Numbers

May 14, 2024 | baystreet.ca

Synlogic Reports First Quarter 2024 Financial Results

May 14, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONVO, IMNN, RLYB, and SYBX Company Descriptions

Imunon NASDAQ:IMNN

$0.55 -0.05 (-8.50%)

Closing price 04:00 PM Eastern

Extended Trading

$0.55 -0.01 (-1.27%)

As of 07:59 PM Eastern

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Organovo NASDAQ:ONVO

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

Rallybio NASDAQ:RLYB

$0.43 -0.02 (-5.43%)

Closing price 04:00 PM Eastern

Extended Trading

$0.43 +0.00 (+0.23%)

As of 07:57 PM Eastern

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

Synlogic NASDAQ:SYBX

$1.74 +0.05 (+2.96%)

Closing price 04:00 PM Eastern

Extended Trading

$1.76 +0.02 (+1.15%)

As of 04:16 PM Eastern

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time